HEMATOLOGY

In separate live virtual events, Pashna N. Munshi, MD; Navneet Majhail, MD, MS; and participants at the respective discussions considered treatment options for a patient with chronic graft-vs-host disease (GVHD) after multiple previous treatment attempts.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with other oncologists concerning the practical considerations for outpatient use of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasm.

The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.

Clinical experiences with belusmosudil are shared among the panel.

The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.

On the heels of promising findings from the phase 3 IMerge study, the FDA has accepted the new drug application of imetelstat for transfusion-dependent anemia in patients with lower-risk MDS.

For patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.

Guillermo Garcia-Manero, MD, discussed 2 studies evaluating therapies for patients with lower-risk myelodysplastic syndrome.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

During a Targeted Oncology™ Case-Based Roundtable™ event, Carrie L. Kitko, MD, discussed whether to biopsy a patient with chronic GVHD and what treatment to use following steroids.

The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.

In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

Two-year follow up data of the phase 3 ASPEN study shows support for the long term benefits of zanubrutinib in patients with previously treated Waldenström macroglobulinemia.

Despite a favorable vote by the Oncologic Drugs Advisory Committee, the FDA has opted not to approve remestemcel-L for the treatment of pediatric steroid-refractory acute graft-vs-host disease.

Ben Derman, MD, discusses next steps for using minimal residual disease-guided discontinuation of maintenance therapy in patients with multiple myeloma.

The phase 1 study is evaluating the combination of a CD19-targeting chimeric antigen receptor and an orthogonal IL-2 in patients with CD19-positive hematologic malignancies.

The REACH3 study showed ruxolitinib to elicit a high efficacy rate and have a manageable safety profile in patients with chronic graft-versus-host disease.

The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.

The group discusses treatment goals and patient education for chronic GVHD.

Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.

Positive topline results from the AGAVE-201 trial have led the companies to submit a biologics license application to the FDA by the end of 2023.